12月23日，塞力医疗（维权）盘中下跌2.07%，截至09:43，报21.73元/股，成交6686.61万元，换手率 1.45%，总市值45.67亿元。 资金流向方面，主力资金净流入9615.86元，特大单买入255.92万元，占比3.83%，卖出0.00元，占比 0.00%；大单买入475.66万元，占比7.11%，卖出730.63万元，占比10.93%。 塞力医疗今年以来股价涨200.97%，近5个交易日涨11.38%，近20日涨1.12%，近60日跌22.70%。 今年以来塞力医疗已经37次登上龙虎榜，最近一次登上龙虎榜为8月26日，当日龙虎榜净买入1.46亿 元；买入总计4.89亿元 ，占总成交额比18.85%；卖出总计3.43亿元 ，占总成交额比13.22%。 资料显示，塞力斯医疗科技集团股份有限公司位于湖北省武汉市东西湖区金山大道1310号，成立日期 2004年2月23日，上市日期2016年10月31日，公司主营业务涉及医疗检验集约化营销及服务业务、体外 诊断产品的代理以及自主体外诊断产品的研发、生产和销售。主营业务收入构成为：IVD业务39.91%， SPD业务38.01%，单纯销售22.08% ...

Core Viewpoint - The stock of Sely Medical has shown significant volatility, with a year-to-date increase of 209.42%, but a recent decline over the past 60 days of 27.63% [1][2]. Group 1: Stock Performance - As of December 19, Sely Medical's stock price was 22.34 yuan per share, with a trading volume of 3.55 billion yuan and a turnover rate of 7.71%, leading to a total market capitalization of 46.95 billion yuan [1]. - The stock has experienced a net outflow of 16.97 million yuan from major funds, with large orders buying 47.49 million yuan and selling 59.06 million yuan [1]. - The stock has appeared on the daily trading leaderboard 37 times this year, with the most recent appearance on August 26, where it recorded a net purchase of 146 million yuan [1]. Group 2: Company Overview - Sely Medical, established on February 23, 2004, and listed on October 31, 2016, is based in Wuhan, Hubei Province, and specializes in medical testing services and in vitro diagnostic products [2]. - The company's revenue composition includes 39.91% from IVD business, 38.01% from SPD business, and 22.08% from pure sales [2]. - The company operates within the pharmaceutical and biological industry, specifically in medical commerce and distribution, with concepts including antigen testing and smart healthcare [2]. Group 3: Financial Performance - For the period from January to September 2025, Sely Medical reported a revenue of 857 million yuan, a year-on-year decrease of 39.64%, and a net profit attributable to shareholders of -87.24 million yuan, down 55.72% year-on-year [2]. - Since its A-share listing, Sely Medical has distributed a total of 27.07 million yuan in dividends, with no dividends paid in the last three years [3]. - As of September 30, 2025, the top ten circulating shareholders included several new institutional investors, indicating a shift in shareholder composition [3].

Core Viewpoint - Shengxiang Biotechnology Co., Ltd. has experienced fluctuations in stock performance, with a year-to-date decline of 14.07% and recent trading activity indicating a slight recovery in the short term [1][2]. Group 1: Stock Performance - On December 18, Shengxiang's stock rose by 2.04%, reaching 19.05 CNY per share, with a trading volume of 46.84 million CNY and a turnover rate of 0.43%, resulting in a total market capitalization of 11.037 billion CNY [1]. - The stock has seen a net inflow of 12.98 thousand CNY from main funds, with significant buying and selling activity, including large orders accounting for 16.49% of purchases and 16.18% of sales [1]. - Over the past five trading days, the stock has increased by 1.17%, while it has decreased by 7.03% over the last 20 days and 6.75% over the last 60 days [1]. Group 2: Company Overview - Shengxiang Biotechnology, established on April 23, 2008, and listed on August 28, 2020, focuses on innovative gene technology, including the development, production, and sales of diagnostic reagents and instruments, as well as third-party medical testing services [2]. - The company's revenue composition includes 87.39% from diagnostic reagents, 5.71% from diagnostic instruments, 4.55% from testing services, and 2.34% from other sources [2]. - As of September 30, 2025, the company reported a revenue of 1.244 billion CNY, reflecting a year-on-year growth of 20.49%, while the net profit attributable to shareholders decreased by 2.10% to 191 million CNY [2]. Group 3: Shareholder Information - Since its A-share listing, Shengxiang has distributed a total of 2.363 billion CNY in dividends, with 967 million CNY distributed over the past three years [3]. - As of September 30, 2025, the number of shareholders increased to 21,600, with an average of 26,772 circulating shares per person, a decrease of 4.01% from the previous period [2][3]. - Among the top ten circulating shareholders, Huabao Zhongzheng Medical ETF holds 9.8053 million shares, a reduction of 1.7872 million shares from the previous period, while Hong Kong Central Clearing Limited is a new shareholder with 3.6601 million shares [3].

Core Viewpoint - Anke Biological has experienced a decline in stock price recently, with a year-to-date increase of 15% but a notable drop in the last 20 and 60 days [1][2] Financial Performance - For the period from January to September 2025, Anke Biological reported a revenue of 1.963 billion yuan, representing a year-on-year growth of 2.15%. However, the net profit attributable to shareholders decreased by 6.48% to 551 million yuan [2] - The company has distributed a total of 2.662 billion yuan in dividends since its A-share listing, with 1.252 billion yuan distributed in the last three years [3] Stock Market Activity - As of December 3, Anke Biological's stock price was 9.65 yuan per share, with a market capitalization of 16.14 billion yuan. The stock has seen a trading volume of 155 million yuan and a turnover rate of 1.31% [1] - The stock has been on the "龙虎榜" (a list of stocks with significant trading activity) once this year, with a net purchase of 193 million yuan on July 31 [1] Shareholder Information - As of November 10, the number of shareholders for Anke Biological was 76,100, a decrease of 1.10% from the previous period. The average number of circulating shares per shareholder increased by 1.11% to 16,062 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and several investment funds, with notable changes in their holdings [3]

Core Points - The stock price of NuoVivian has decreased by 2.07% to 21.76 CNY per share, with a total market capitalization of 8.655 billion CNY [1] - The company has experienced a year-to-date stock price decline of 1.18%, with a 4.27% drop over the last five trading days [1] - NuoVivian's main business includes the research and development of functional proteins and high molecular organic materials, with a revenue composition of 81.86% from biological reagents [1] Financial Performance - As of September 30, NuoVivian reported a total of 9,447 shareholders, an increase of 9.90% from the previous period [2] - For the period from January to September 2025, the company achieved a revenue of 952 million CNY, a year-on-year decrease of 3.40% [2] - The net profit attributable to the parent company was 6.6152 million CNY, reflecting a significant year-on-year decrease of 63.57% [2] Dividend Information - Since its A-share listing, NuoVivian has distributed a total of 731 million CNY in dividends, with 611 million CNY distributed over the past three years [3]

Core Viewpoint - Wante Bio's stock has experienced a significant decline in 2023, with a year-to-date drop of 31.81% and a recent 20-day decline of 13.58% [2] Company Overview - Wante Bio, established on April 24, 1991, and listed on April 29, 2020, is located in Changping District, Beijing. The company specializes in the research, production, and sales of in vitro diagnostic reagents, instruments, and vaccines [2] - The revenue composition of Wante Bio includes: diagnostic reagents (67.06%), vaccines (20.36%), diagnostic instruments (4.98%), agency products (4.97%), other (1.88%), and active raw materials (0.76%) [2] - As of September 30, 2025, Wante Bio had 42,000 shareholders, an increase of 9.41% from the previous period, with an average of 30,124 circulating shares per shareholder, a decrease of 8.60% [2] Financial Performance - For the period from January to September 2025, Wante Bio reported a revenue of 1.498 billion yuan, a year-on-year decrease of 23.09%, and a net profit attributable to shareholders of -173 million yuan, a year-on-year decrease of 165.04% [2] - Since its A-share listing, Wante Bio has distributed a total of 1.541 billion yuan in dividends, with 1.311 billion yuan distributed over the past three years [3] Shareholder Structure - As of September 30, 2025, the top ten circulating shareholders of Wante Bio include Hong Kong Central Clearing Limited, which holds 12.8991 million shares (a decrease of 9.8553 million shares), and Huatai-PB CSI 300 ETF, holding 6.4061 million shares (a decrease of 318,300 shares) [3] - The newly entered shareholder in the top ten is the China National Securities Biomedicine Index A, holding 4.9609 million shares [3]

Core Viewpoint - Wante Bio's stock has experienced a significant decline this year, with a 30.39% drop, and the company is facing challenges in revenue and profit margins [1][2]. Financial Performance - For the period from January to September 2025, Wante Bio reported a revenue of 1.498 billion yuan, a year-on-year decrease of 23.09% [2]. - The net profit attributable to the parent company was -173 million yuan, reflecting a year-on-year decrease of 165.04% [2]. Stock Market Activity - As of December 1, Wante Bio's stock price was 49.05 yuan per share, with a market capitalization of 62.054 billion yuan [1]. - The stock has seen a trading volume of 1.06 billion yuan, with a turnover rate of 0.17% [1]. - The stock has experienced a decline of 4.76% over the last five trading days and 11.21% over the last 20 days [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 42,000, a rise of 9.41% [2]. - The average number of circulating shares per shareholder decreased by 8.60% to 30,124 shares [2]. Dividend Distribution - Wante Bio has distributed a total of 1.541 billion yuan in dividends since its A-share listing, with 1.311 billion yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the fifth-largest circulating shareholder, holding 12.8991 million shares, a decrease of 9.8553 million shares from the previous period [3]. - The top ten circulating shareholders included new entrants and exits, indicating changes in institutional interest [3].

Core Viewpoint - Wante Bio's stock has experienced a significant decline in 2023, with a year-to-date drop of 31.73% and a recent 60-day decline of 17.40% [2] Company Overview - Wante Bio, established on April 24, 1991, and listed on April 29, 2020, is located in Changping District, Beijing. The company specializes in the research, production, and sales of in vitro diagnostic reagents, instruments, and vaccines [2] - The revenue composition of Wante Bio includes: diagnostic reagents (67.06%), vaccines (20.36%), diagnostic instruments (4.98%), agency products (4.97%), other (1.88%), and active raw materials (0.76%) [2] - As of September 30, 2025, Wante Bio had 42,000 shareholders, an increase of 9.41% from the previous period, with an average of 30,124 circulating shares per shareholder, a decrease of 8.60% [2] Financial Performance - For the period from January to September 2025, Wante Bio reported a revenue of 1.498 billion yuan, a year-on-year decrease of 23.09%, and a net profit attributable to shareholders of -173 million yuan, a year-on-year decrease of 165.04% [2] - Since its A-share listing, Wante Bio has distributed a total of 1.541 billion yuan in dividends, with 1.311 billion yuan distributed over the past three years [3] Shareholder Structure - As of September 30, 2025, the top ten circulating shareholders of Wante Bio include Hong Kong Central Clearing Limited, which holds 12.8991 million shares (a decrease of 9.8553 million shares), and Huatai-PB CSI 300 ETF, holding 6.4061 million shares (a decrease of 318,300 shares) [3] - The China National Securities Bio-Medical Index A has entered the top ten circulating shareholders with 4.9609 million shares as a new shareholder, while E Fund CSI 300 Medical ETF has exited the list [3] Market Activity - On November 28, Wante Bio's stock price fell by 2.02%, trading at 48.10 yuan per share, with a total transaction volume of 131 million yuan and a turnover rate of 0.21%. The total market capitalization is 60.852 billion yuan [1] - In terms of capital flow, there was a net outflow of 17.3687 million yuan from main funds, with large orders showing a buy of 23.094 million yuan (17.66%) and a sell of 27.222 million yuan (20.82%) [1]

Core Viewpoint - Haishun New Materials has experienced fluctuations in stock price and financial performance, with a notable decrease in net profit year-on-year, indicating potential challenges in the market [1][2]. Financial Performance - As of September 30, 2025, Haishun New Materials reported a revenue of 823 million yuan, a year-on-year decrease of 0.42% [2]. - The net profit attributable to shareholders was 48.67 million yuan, reflecting a significant year-on-year decline of 38.96% [2]. - The company has distributed a total of 296 million yuan in dividends since its A-share listing, with 139 million yuan distributed over the past three years [3]. Stock Market Activity - On November 27, the stock price increased by 2.12%, reaching 16.35 yuan per share, with a trading volume of 24.93 million yuan and a turnover rate of 1.23% [1]. - The total market capitalization of Haishun New Materials is 3.164 billion yuan [1]. - Year-to-date, the stock price has risen by 24.92%, but it has seen a decline of 4.27% over the last five trading days [1]. Shareholder Information - The number of shareholders as of September 30, 2025, is 13,500, a decrease of 12.81% from the previous period [2]. - The average number of circulating shares per shareholder is 9,274, which has increased by 14.69% [2]. - The top ten circulating shareholders include a new entrant, the Medical Device ETF (159883), holding 717,800 shares [3]. Company Overview - Haishun New Materials, established on January 18, 2005, specializes in the research, production, and sales of high-barrier packaging materials that come into direct contact with pharmaceuticals [1]. - The company's main business revenue composition is 89.58% from new pharmaceutical packaging materials and 10.42% from other sources [1]. - The company operates within the light industry manufacturing sector, specifically in packaging and printing [1].

Core Viewpoint - Aomei Medical has shown a significant stock price increase of 30.78% year-to-date, despite a recent decline of 5.66% over the last five trading days, indicating volatility in its stock performance [1][2]. Financial Performance - For the period from January to September 2025, Aomei Medical reported a revenue of 2.597 billion yuan, representing a year-on-year growth of 5.98% [2]. - The net profit attributable to shareholders for the same period was 349 million yuan, reflecting a substantial year-on-year increase of 31.54% [2]. Stock Market Activity - As of November 25, Aomei Medical's stock price was 11.34 yuan per share, with a market capitalization of 7.181 billion yuan [1]. - The stock experienced a trading volume of 48.9651 million yuan, with a turnover rate of 0.96% [1]. - The net inflow of main funds was 2.4763 million yuan, with large orders accounting for 13.00% of purchases and 7.94% of sales [1]. Shareholder Information - As of September 30, 2025, Aomei Medical had 37,800 shareholders, an increase of 0.71% from the previous period [2]. - The average number of circulating shares per shareholder was 11,965, which decreased by 0.71% [2]. - The company has distributed a total of 1.099 billion yuan in dividends since its A-share listing, with 91.9131 million yuan distributed over the last three years [3]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the fifth-largest circulating shareholder, holding 17.9166 million shares, an increase of 5.5221 million shares from the previous period [3]. - The Medical Device ETF (159883) was noted as a new tenth-largest circulating shareholder, holding 1.5656 million shares [3].